<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">24900715</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1948-5875</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>7</Issue><PubDate><Year>2013</Year><Month>Jul</Month><Day>11</Day></PubDate></JournalIssue><Title>ACS medicinal chemistry letters</Title><ISOAbbreviation>ACS Med Chem Lett</ISOAbbreviation></Journal><ArticleTitle>Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections.</ArticleTitle><Pagination><StartPage>585</StartPage><EndPage>589</EndPage><MedlinePgn>585-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/ml400095m</ELocationID><Abstract><AbstractText>Rhinovirus (genus enterovirus) infections are responsible for many of the severe exacerbations of asthma and chronic obstructive pulmonary disease. Other members of the genus can cause life-threatening acute neurological infections. There is currently no antiviral drug approved for the treatment of such infections. We have identified a series of potent, broad-spectrum antiviral compounds that inhibit the replication of the human rhinovirus, Coxsackie virus, poliovirus, and enterovirus-71. The mechanism of action of the compounds has been established as inhibition of a lipid kinase, PI4KIII&#x3b2;. Inhibition of hepatitis C replication in a replicon assay correlated with enterovirus inhibition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>MacLeod</LastName><ForeName>Angus M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Medicinal Chemistry Department, BioFocus , Chesterford Research Park, Cambridge, CB10 1XL, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Dale R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Medicinal Chemistry Department, BioFocus , Chesterford Research Park, Cambridge, CB10 1XL, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Medicinal Chemistry Department, BioFocus , Chesterford Research Park, Cambridge, CB10 1XL, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van de Po&#xeb;l</LastName><ForeName>Herv&#xe9;</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medicinal Chemistry Department, BioFocus , Chesterford Research Park, Cambridge, CB10 1XL, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conrath</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Galapagos NV , Generaal de Wittelaan, 2800 Mechelen, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Galapagos NV , Generaal de Wittelaan, 2800 Mechelen, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyssen</LastName><ForeName>Pieter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven , Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neyts</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven , Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Med Chem Lett</MedlineTA><NlmUniqueID>101521073</NlmUniqueID><ISSNLinking>1948-5875</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HCV</Keyword><Keyword MajorTopicYN="N">PI4KIII&#x3b2;</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">inhibitor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24900715</ArticleId><ArticleId IdType="pmc">PMC4030314</ArticleId><ArticleId IdType="doi">10.1021/ml400095m</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Papi A.; Bellettato C. M.; Braccioni F.; Romagnoli M.; Casolari P.; Caramori G.; Fabbri L. M.; Johnston S. L. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006, 173, 1114&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pubmed">16484677</ArticleId></ArticleIdList></Reference><Reference><Citation>Corne J. M.; Marshall C.; Smith S.; Schreiber J.; Sanderson G.; Holgate S. T.; Johnston S. L. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet 2002, 359, 831&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">11897281</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallia P.; Contoli M.; Caramori G.; Pandit A.; Johnston S. L.; Papi A. Exacerbations of asthma and chronic obstructive pulmonary disease (COPD): focus on virus induced exacerbations. Curr. Pharm. Des. 2007, 13173&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17266589</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. World health statistics 2008. http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf.</Citation></Reference><Reference><Citation>Hayden F. G.; Turner R. B.; Gwaltney J. M.; Chi-Burris K.; Gersten M.; Hsyu P.; Patick A. K.; Smith G. J.; Zalman L. S. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob. Agents Chemother. 2003, 47123907&#x2013;3916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC296196</ArticleId><ArticleId IdType="pubmed">14638501</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F. G.; Hipskind G. J.; Woerner D. H.; Eisen G. F.; Janssens M.; Janssen P. A. J.; Andries K. Intranasal Pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob. Agents Chemother. 1995, 392290&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC162529</ArticleId><ArticleId IdType="pubmed">7726484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F. G.; Herrington D. T.; Coats T. L.; Kim K.; Cooper E. C.; Villano S. A.; Liu S.; Hudson S.; Pevear D. C.; Collett M.; McKinlay M. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin. Infect. Dis. 2003, 36121523&#x2013;1532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199898</ArticleId><ArticleId IdType="pubmed">12802751</ArticleId></ArticleIdList></Reference><Reference><Citation>Feil S. C.; Hamilton S.; Krippner G. Y.; Lin B.; Luttick A.; McConnell D. B.; Nearn R.; Parker M. W.; Ryan J.; Stanislawski P. C.; Tucker S. P.; Watson K. G.; Morton C. J. An orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirus. ACS Med. Chem. Lett. 2012, 34303&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4025830</ArticleId><ArticleId IdType="pubmed">24900468</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma A. M.; Vliegen I.; De Clercq E.; Neyts J. Selective inhibitors of picornavirus replication. Med. Res. Rev. 2008, 286823&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">18381747</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett S. Polio eradication: strengthening the weakest links. Health Aff. 2009, 2841079&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pubmed">19597207</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P. C. Recent advances in the molecular epidemiology and control of human enterovirus 71 infection. Curr. Opin. Virol. 2012, 22199&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">22482716</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleischer R.; Laessig K. Safety and efficacy evaluation of pleconaril for treatment of the common cold. Clin. Infect. Dis. 2003, 37121722.</Citation><ArticleIdList><ArticleId IdType="pubmed">14689362</ArticleId></ArticleIdList></Reference><Reference><Citation>Borawski J.; Troke P.; Puyang X.; Gibaja V.; Zhao S.; Mickanin C.; Leighton-Davies J.; Wilson C. J.; Myer V.; Cornellataracido I.; Baryza J.; Tallarico J.; Joberty G.; Bantscheff M.; Schirle M.; Bouwmeester T.; Mathy J. E.; Lin K.; Compton T.; Labow M.; Wiedmann B.; Gaither L. A. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J. Virol. 2009, 831910058&#x2013;10074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748049</ArticleId><ArticleId IdType="pubmed">19605471</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss S.; Rebhan I.; Backes P.; Romero-Brey I.; Erfle H.; Matula P.; Kaderali L.; Poenisch M.; Blankenburg H.; Hiet M. S.; Longerich T.; Diehl S.; Ramirez F.; Balla T.; Rohr K.; Kaul A.; B&#xfc;hler S.; Pepperkok R.; Lengauer T.; Albrecht M.; Eils R.; Schirmacher P.; Lohmann V.; Bartenschlager R. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microb. 2011, 9132&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433060</ArticleId><ArticleId IdType="pubmed">21238945</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger K. L.; Cooper J. D.; Heaton N. S.; Yoon R.; Oakland T. E.; Jordan T. X.; Mateu G.; Grakoui A.; Randall G. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Natl. Acad. Sci. U.S.A. 2009, 106187577&#x2013;7582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678598</ArticleId><ArticleId IdType="pubmed">19376974</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu N. Y.; Ilnytska O.; Belov G.; Santiana M.; Chen Y. H.; Takvorian P. M.; Pau C.; van der Schaar H.; Kaushik-Basu N.; Balla T.; Cameron C. E.; Ehrenfeld E.; van Kuppeveld F. J.; Altan-Bonnet N. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 2010, 1415799&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2982146</ArticleId><ArticleId IdType="pubmed">20510927</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M.; Kojima H.; Nagano T.; Okabe T.; Wakita T.; Shimizu H. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J. Virol. 2011, 8552364&#x2013;2372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067798</ArticleId><ArticleId IdType="pubmed">21177810</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianco A.; Reghellin V.; Donnici L.; Fenu S.; Alvarez R.; Baruffa C.; Peri F.; Pagani M.; Abrignani S.; Neddermann P.; De Francesco R. PLoS Pathog. 2012, 83e1002576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297592</ArticleId><ArticleId IdType="pubmed">22412376</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamarche M. J.; Borawski J.; Bose A.; Capacci-Daniel C.; Colvin R.; Dennehy M.; Ding J.; Dobler M.; Drumm J.; Gaither L. A.; Gao J.; Jiang X.; Lin K.; McKeever U.; Puyang X.; Raman P.; Thohan S.; Tommasi R.; Wagner K.; Xiong X.; Zabawa T.; Zhu S.; Wiedmann B. Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors. Antimicrob. Agents Chemother. 2012, 56105149&#x2013;5156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3457382</ArticleId><ArticleId IdType="pubmed">22825118</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>